Lipid peroxidation is increased in paraoxonase L55 homozygotes compared with M-allele carriers

References

• Mackness M.I., Abbott C.A., Arrol S., Durrington P.N. The role of high-density and lipid soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochemical Journal 1993; 294: 829–835
   PubMed Web of Science ®Google Scholar
• Mackness B., Mackness M.I., Arrol S., Turkie W., Durrington P.N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Letters 1998; 423: 57–60
   PubMed Web of Science ®Google Scholar
• Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genetics 1996; 14: 334–336
   PubMed Web of Science ®Google Scholar
• Morrow J.D., Awad J.A., Boss H.J., Blair I.A., Robert L.J.I. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proceedings of the National Academy of Sciences of the USA 1992; 89: 10721–10725
   PubMed Web of Science ®Google Scholar
• Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F., Roberts L.J.I. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proceedings of the National Academy of Sciences of the USA 1990; 87: 9383–9387
   PubMed Web of Science ®Google Scholar
• Morrow J.D., Minton T.A., Badr K.F., Roberts L.J.I. Evidence that the F2-isoprostane, 8-epi-prostaglandin F2alpha, is formed in vivo. Biochimica et Biophysica Acta 1994; 1210: 244–248
   PubMed Web of Science ®Google Scholar
• Takahashi K., Nammour T.M., Fukunaga M., Ebert J., Morrow J.D., Roberts L.J.I., Hoover R.L., Badr K.F. Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2alpha, in the rat: evidence for interaction with thromboxane A2 receptors. Journal of Clinical Investigation 1992; 90: 136–141
   PubMed Web of Science ®Google Scholar
• Kang K.H., Morrow J.D., Roberts L.J.I., Newman J.H., Banerjee M. Airway and vascular effects of 8-epi-prostaglandin F2 alpha in isolated perfused rat lung. Journal of Applied Physiology 1993; 74: 460–465
   PubMed Web of Science ®Google Scholar
• Morrow J.D., Minton T.A., Roberts L.J. The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endopeoxidase receptor antagonist. Prostaglandins 1992; 44: 155–163
   PubMedGoogle Scholar
• Morrow J.D., Frei B., Longmire A.W., Caziano J.M., Lynch S.M., Shyr Y., Strauss W.E., Oates J.A., Roberts L.J.I. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage. New England Journal of Medicine 1995; 332: 1198–1203
   PubMed Web of Science ®Google Scholar
• Morrow J.D., Moore K.P., Awad J.A., Ravenscraft M.D., Marini G., Badr K.F., Williams R., Roberts L.J.I. Marked overproduction of non-cyclooxygenase derived prostanoids (F2-isoprostanes) in the hepatorenal syndrome. Journal of Lipid Mediation 1993; 6: 417–420
   PubMedGoogle Scholar
• Gopaul N.K., Änggård E.E., Mallet A.I., Betteridge D.J., Wolff C., Nourooz-Zadeh J. Plasma 8-epi-PGF2alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Letters 1995; 368: 225–229
   PubMed Web of Science ®Google Scholar
• Catella F., Reilly M.P., Delanty N., Lawson J.A., Moran N., Meagher E., FitzGerald G.A. Physiological formation of 8-epi-PGF2α in vivo is not affected by cyclooxygenase inhibition. Advances in Prostaglandin, Tromboxane, and Leukotriene Research 1995; 23: 233–236
   PubMedGoogle Scholar
• Wirta O.R., Pasternack A.I. Glomerular filtration rate and kidney size in type 2 (non-insulin-dependent) diabetes mellitus. Clinical Nephrology 1995; 44: 1–7
   PubMed Web of Science ®Google Scholar
• Kirkendall W.M., Feinleib M., Freis E.D., Mark A.L. Recommendations for human blood pressure determination by sphygmomanometers. Circulation 1980; 62: 1146–1146
   PubMed Web of Science ®Google Scholar
• Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density-lipoprotein cholesterol in plasma, without use of the preparative ultrasentrifuge. Clinical Chemistry 1972; 18: 499–502
   PubMed Web of Science ®Google Scholar
• Garnett E.S., Parsons V., Veall N. Measurement of glomerular filtration-rate in man using a 51Cr-edetic-acid complex. Lancet 1967; 15: 818–819
   Google Scholar
• Frei B., Stocker R., Ames B.N. Antioxidant defences and lipid peroxidation in human blood plasma. Proceedings of the National Academy of Sciences of the USA 1988; 88: 9748–9752
   Google Scholar
• Catignani G., Bieri J. Simultaneous determination of retinol and alpha-tocopherol in serum or plasma by liquid chromatography. Clinical Chemistry 1983; 29: 708–712
   PubMed Web of Science ®Google Scholar
• Ellman G. Tissue sulphydryl groups. Archives of Biochemistry and Biophysics 1993; 82: 70–77
   Google Scholar
• Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genetics 1993; 3: 73–76
   PubMed Web of Science ®Google Scholar
• McElveen J., Mackness M.I., Colley C.M., Peard T., Warner S., Walker C.H. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clinical Chemistry 1986; 32: 671–673
   PubMed Web of Science ®Google Scholar
• Secchiero S., Mussap M., Zaninotto M., Bertorelle R., Burlina A. Serum arylesterase (paraoxonase) activity following myocardial infarction. Clinica Chimica Acta 1989; 183: 71–75
   PubMed Web of Science ®Google Scholar
• Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. Journal of Clinical Investigation 1995; 96: 2882–2891
   PubMed Web of Science ®Google Scholar
• Watson A.D., Leitinger N., Navab M., Faull K.F., Horkko S., Witztum J.L., Palinski W., Schwenke D., Salomon R.G., Sha W., Subbanagounder G., Fogelman A.M., Berliner J.A. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. Journal of Biological Chemistry 1997; 23: 13597–13607
   Google Scholar
• Zama T., Murata M., Matsubara Y., Kawano K., Aoki N., Yoshino H., Watanabe G., Ishikawa K., Ikeda Y. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arteriosclerosis, Thrombosis and Vascular Biology 1997; 17: 3565–3569
   PubMed Web of Science ®Google Scholar
• Garin M.C., James R.W., Dussoix P., Blanche H., Passa P., Froguel P., Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. Journal of Clinical Investigation 1997; 99: 62–66
   PubMed Web of Science ®Google Scholar
• Schmidt H., Schmidt R., Niederkorn K., Gradert A., Schumacher M., Watzinger N., Hartung H.P., Kostner G.M. Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke 1998; 29: 2043–2048
   PubMed Web of Science ®Google Scholar